Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472056 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00472056: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00472056 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00472056, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Cohort 1: Patients who are less than or equal to 65 years of age. 1\. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) 2. To determine the treatment related mortality (TRM)
Interventions
- DRUG Melphalan
- DRUG Rituximab
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472056
The ClinicalTrials.gov registry entry for NCT00472056 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00472056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472056 about?
NCT00472056 is a clinical study titled "Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies". Cohort 1: Patients who are less than or equal to 65 years of age. 1\. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1. To determine the disease-free survival (DFS) in the 2 arms (standard...
What is the current status of trial NCT00472056?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2005-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00472056?
The interventions under investigation include: Melphalan (DRUG), Rituximab (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG).
Who is sponsoring clinical trial NCT00472056?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.